Intuitive Surgical Inc

Intuitive Surgical’s Q1 2026 stock dip is a market correction, not a business crash—analysts still see upside from growing da Vinci 5 procedure volumes, but valuation and reimbursement shifts warrant careful monitoring.

Intuitive Surgical’s analyst coverage shows steady growth amid rising competition, highlighting the da Vinci system’s innovation, market leadership, and future challenges.

Intuitive Surgical Q1 2026 earnings show strong revenue growth, expanding recurring streams, AI‑enhanced da Vinci 5 adoption and a bullish analyst outlook.

Intuitive Surgical’s Q1 earnings beat estimates, driven by da Vinci 5 sales, expanding recurring revenue and stronger margins—boosting shares and analyst optimism.

Intuitive Surgical’s Q4 2025 outlook shows 10% EPS growth and 16% revenue lift, driven by expanding da Vinci installations, consumables, and AI‑powered robotics—an indicator of continued market dominance amid rising global healthcare spend.

Intuitive Surgical’s Q1 2026 earnings preview: investors eye revenue, cost control and next‑gen robotics amid a tightened market and shifting central‑bank policies.

Intuitive Surgical’s market dip masks a strong clinical track record, new robotic releases, and a robust safety profile—key insights for investors and patients alike.

Intuitive Surgical’s Q4 earnings forecast shows modest EPS growth and revenue gains driven by robotic‑surgery demand, analyst upgrades, and a rising price target.

Intuitive Surgical consolidates da Vinci and Ion distribution across Italy, Spain, Portugal, Malta, and San Marrio, boosting support, training, and regulatory compliance while improving patient outcomes and reducing downtime.

Discover why institutional investors keep buying Intuitive Surgical shares, the strengths and risks of its robotic‑surgery dominance, and emerging data‑monetization opportunities that could shape future growth.